Overview

Dapagliflozin DPPIV Inhibitor add-on Study

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Bristol-Myers Squibb
Treatments:
Dapagliflozin